National Cancer Institute / National Human Genome Research Institute / Jude Children’s Research Hospital / National Institute of Neurological Disorders / Emory University / /
IndustryTerm
brain tumor treatment / health insurance costsharing / cancer treatment / brain tumor therapies / health insurance plans / /
MedicalCondition
chronic neurological problems / adult glioblastoma therapy / Pediatric brain tumors / high-grade gliomas / cancer / disease / benign brain tumor / neurologic disease / prevalent pediatric brain tumor / medulloblastoma metastasis / very few new brain tumor / gliomas / pediatric brain tumor / Diffuse Intrinsic Pontine Glioma / malignant brain tumors / deadliest cancers / We Must Do More To Fight Childhood Brain Tumors / brain tumor / Brain tumors / Childhood Brain Tumors / /
MedicalTreatment
chemotherapy / /
Organization
National Institute of Neurological Disorders and Stroke / National Cancer Institute / Emory University / Congress / National Human Genome Research Institute / National Institute of Health / Jude Children’s Research Hospital / U.S. Food and Drug Administration / National Center for Advancing Translational Sciences / Department of Defense / Baylor University / National Brain Tumor Society / /
Person
Kirk / Franken / Elizabeth / Lauren / David F. Arons / /
Position
Advocate / /
Product
Temodar / /
Technology
Chemotherapy / Human Genome / Drug Development / /
Public Policy Issue Brief Appropriations for Medical Research and Drug Approval: Ensuring Support for Brain Tumor Research and Drug Development Background • There have been very few new brain tumor therapies approved